Benitec Biopharma Inc.
BNTC
$12.37
-$0.63-4.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.28M | 7.54M | 6.43M | 13.48M | 8.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.58M | 13.38M | 9.80M | 17.18M | 15.34M |
| Operating Income | -13.58M | -13.38M | -9.80M | -17.18M | -15.34M |
| Income Before Tax | -11.94M | -11.84M | -8.97M | -16.15M | -14.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.94M | -11.84M | -8.97M | -16.15M | -14.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.94M | -11.84M | -8.97M | -16.15M | -14.50M |
| EBIT | -13.58M | -13.38M | -9.80M | -17.18M | -15.34M |
| EBITDA | -13.57M | -13.36M | -9.79M | -17.16M | -15.32M |
| EPS Basic | -0.24 | -0.26 | -0.22 | -0.39 | -0.38 |
| Normalized Basic EPS | -0.15 | -0.16 | -0.13 | -0.25 | -0.23 |
| EPS Diluted | -0.24 | -0.26 | -0.22 | -0.39 | -0.38 |
| Normalized Diluted EPS | -0.15 | -0.16 | -0.13 | -0.25 | -0.23 |
| Average Basic Shares Outstanding | 49.39M | 45.97M | 41.52M | 41.16M | 38.60M |
| Average Diluted Shares Outstanding | 49.39M | 45.97M | 41.52M | 41.16M | 38.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |